AF
ABCL icon

Aviso Financial’s AbCellera Biologics ABCL Stock Holding History

Aviso Financial’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,540
Closed -$22.8K – 274
2026
Q1 		$22.8K Hold
6,540
– – ﹤0.01% 267
2025
Q4 		$22.4K Hold
6,540
– – ﹤0.01% 261
2025
Q3 		$32.9K Hold
6,540
– – ﹤0.01% 256
2025
Q2 		$22.4K Hold
6,540
– – ﹤0.01% 265
2025
Q1 		$14.6K Hold
6,540
– – ﹤0.01% 278
2024
Q4 		$19.2K Hold
6,540
– – ﹤0.01% 282
2024
Q3 		$17K Buy
+6,540
New +$18.1K ﹤0.01% 294

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Aviso Financial's ABCL Position: Q2 2026 in Review

Aviso Financial sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 6,540 shares — an estimated $22.8K sold.

Aviso Financial first reported a position in ABCL in Q3 2024 and held it in 7 quarters. The position peaked at $32.9K in Q3 2025. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Aviso Financial reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
  • Aviso Financial sold 6,540 AbCellera Biologics shares in Q2 2026, an estimated $22.8K.
  • Aviso Financial first reported a position in AbCellera Biologics in Q3 2024 and held it in 7 quarters.
  • Aviso Financial's AbCellera Biologics position peaked at $32.9K in Q3 2025.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Aviso Financial's 13F filing for Q2 2026, filed 13 Aug 2026.